Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program

@inproceedings{Ajluni2016EfficacyAS,
  title={Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program},
  author={Nevin Ajluni and Moahad S. Dar and John Xu and Adam H Neidert and Elif A Oral},
  booktitle={Journal of diabetes & metabolism},
  year={2016}
}
OBJECTIVE Patients with lipodystrophy have severe metabolic abnormalities (insulin resistance, diabetes, and hypertriglyceridemia) that may increase morbidity and mortality. Metreleptin is approved by the United States Food and Drug Administration for treatment of generalized forms of lipodystrophy. We aimed to determine the efficacy and safety of… CONTINUE READING